Actavis’ acquisition of Allergan gets EU nod

European Commission clears Actavis’ pending acquisition of Allergan


The company has purchased Allergan for $66 billion

Actavis has announced that the company has received clearance from the European Commission for its pending acquisition of Allergan.

Clearance by the European Commission satisfies the final regulatory condition to the closing of the pending acquisition, which remains subject to certain customary closing conditions and is expected to be effective on or around March 17, 2015.

Actavis has acquired Allergan for $66 billion.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email